Christopher Yea Net Worth

The estimated Net Worth of Christopher Yea is at least $3.64 Milión dollars as of 22 August 2024. Mr. Yea owns over 3,125 units of KalVista Pharmaceuticals Inc stock worth over $938,986 and over the last 8 years he sold KALV stock worth over $1,773,567. In addition, he makes $926,044 as Chief Development Officer at KalVista Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Yea KALV stock SEC Form 4 insiders trading

Christopher has made over 25 trades of the KalVista Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 3,125 units of KALV stock worth $33,500 on 22 August 2024.

The largest trade he's ever made was selling 39,886 units of KalVista Pharmaceuticals Inc stock on 14 February 2024 worth over $598,689. On average, Christopher trades about 5,735 units every 57 days since 2016. As of 22 August 2024 he still owns at least 87,592 units of KalVista Pharmaceuticals Inc stock.

You can see the complete history of Mr. Yea stock trades at the bottom of the page.

Christopher Yea biography

Christopher M. Yea Ph.D. serves as Chief Development Officer of the Company. He served as the Chief Development Officer of KalVista Limited since November 2015 and became our Chief Development Officer as of November 2016. Prior to joining us, he was the Chief Operating Officer at Vantia, Ltd. from its spin-out from Ferring Pharmaceuticals in 2008, until November 2015. Prior to the spin-out of Vantia, Dr. Yea led the Biology group and was responsible for transition of candidates into development at Ferring Pharmaceuticals. Following post-doctoral work he spent several years at Roussel-UCLAF and Hoechst Marion Roussel. Dr. Yea holds a B.Sc. and a Ph.D. in Biochemistry from the University of Bristol, UK.

What is the salary of Christopher Yea?

As the Chief Development Officer of KalVista Pharmaceuticals Inc, the total compensation of Christopher Yea at KalVista Pharmaceuticals Inc is $926,044. There are 4 executives at KalVista Pharmaceuticals Inc getting paid more, with Thomas Crockett having the highest compensation of $1,731,160.

How old is Christopher Yea?

Christopher Yea is 56, he's been the Chief Development Officer of KalVista Pharmaceuticals Inc since 2016. There are 8 older and 8 younger executives at KalVista Pharmaceuticals Inc. The oldest executive at KalVista Pharmaceuticals Inc is Arnold Oronsky, 80, who is the Independent Director.

What's Christopher Yea's mailing address?

Christopher's mailing address filed with the SEC is C/O KALVISTA PHARMACEUTICALS, INC, 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE, MA, 02142.

Insiders trading at KalVista Pharmaceuticals Inc

Over the last 8 years, insiders at KalVista Pharmaceuticals Inc have traded over $74,823,944 worth of KalVista Pharmaceuticals Inc stock and bought 4,877,063 units worth $58,591,487 . The most active insiders traders include Holdings A/S Novo, Capital Management, L.P.Ra ... a Rajeev M. Shah. On average, KalVista Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $835,088. The most recent stock trade was executed by Benjamin L Palleiko on 6 September 2024, trading 15,625 units of KALV stock currently worth $167,500.

What does KalVista Pharmaceuticals Inc do?

kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.

Complete history of Mr. Yea stock trades at KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals Inc executives and stock owners

KalVista Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Thomas Crockett,
  Chief Executive Officer, Director
• Edward Feener,
  Chief Scientific Officer
• Benjamin Palleiko,
  Chief Financial Officer, Chief Business Officer
• Thomas Andrew Crockett M.B.A.,
  CEO & Director
• Christopher Yea,
  Chief Development Officer
• Benjamin L. Palleiko,
  Chief Bus. Officer & CFO
• Dr. Christopher M. Yea Ph.D.,
  Chief Devel. Officer
• Martin Edwards,
  Independent Chairman of the Board
• Edward Unkart,
  Independent Director
• Arnold Oronsky,
  Independent Director
• Albert Cha,
  Independent Director
• Brian Pereira,
  Independent Director
• Daniel Soland,
  Independent Director
• Michael Smith,
  Senior Vice President - Development
• Andreas Maetzel,
  Senior Vice President - Medical
• Jarrod Aldom,
  VP of Corp. Communications
• John B. McKune,
  VP of Fin.
• Stephen Donnelly,
  Director of Fin. and Company Sec.
• Dr. Paul K. Audhya M.B.A., M.D.,
  Chief Medical Officer
• Dr. Michael D. Smith Pharm.D.,
  Sr. VP of Devel.
• Rachel Morten,
  Head of Regulatory Affairs and QA
• Leah Monteiro,
  Sr. Director of Corp. Communications & Investor Relations
• Dr. Edward P. Feener Ph.D.,
  Chief Scientific Officer
• Joshua Resnick,
  Director
• Iv, Llcsv Life Sciences Fun...,
  
• Capital Management, Llc Kol...,
  
• Capital Management, L.P.Ra ...,
  
• Rajeev M. Shah,
  Director
• Healthcare Capital Partners...,
  
• Holdings A/S Novo,
  10% owner
• William Fairey,
  
• Paul K. Audhya,
  CHIEF MEDICAL OFFICER
• Healthcare Capital Partners...,
  
• Nancy Stuart,
  Director
• Patrick Treanor,
  Director
• Brian Piekos,
  Chief Financial Officer
• Healthcare Capital Partners...,